Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine combined with esketamine or sufentanil in percutaneous lung tumor ablation
ChiCTR2100050021Phase 4Recruiting
- Sponsor
- Hangzhou First People's Hospital
- Start
- Jun 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in lung neoplasm comparing Esketamine + dexmedetomidine with Sufentanil + dexmedetomidine (2 arms). Primary endpoint: pain response score. Started Jun 2021; status: recruiting.
02
Drugs
dexmedetomidineesketaminesufentanil
03
Conditions
lung neoplasm
Beyond the preview
Go deeper on ChiCTR2100050021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050021.